Sponsored Supplement
A Treatment Option for Patients with Relapsed/Refractory AML
This supplement is sponsored and developed by Bristol-Myers Squibb Company.
December 1, 2021|Federal Practitioner
Over the past 5 years, the prognosis for patients with acute myeloid leukemia (AML) has changed markedly, thanks to the development and approval of several therapeutic agents.1 This supplement to Federal Practitioner reviews a once-daily oral formulation for relapsed/refractory patients with AML.
Click here to read the supplement.
11/21 HE-US-2100483
,1. Bohl SR, Bullinger L, Rücker FG. New targeted agents in acute myeloid leukemia: new hope on the rise. Int J Mol Sci. 2019;20(8):1983.